[ORGANIZATION]
Phase 3 COAST‑1 trial
Featured in 1 tracked story · first seen
Situations
Sanofi halts Amlitelimab development
2 clusters · 11 sources · last updated
Latest: Sanofi Halts Development of Amlitelimab for Atopic Dermatitis
In late July 2026, Sanofi announced it would stop pursuing its experimental antibody Amlitelimab for atopic dermatitis. The company cited insufficient efficacy and safety data from the Phase 3 COAST‑1 trial, including is